Published in Am J Reprod Immunol on March 01, 2012
Endogenous airway mucins carry glycans that bind Siglec-F and induce eosinophil apoptosis. J Allergy Clin Immunol (2014) 2.20
Lectin galactoside-binding soluble 3 binding protein (LGALS3BP) is a tumor-associated immunomodulatory ligand for CD33-related Siglecs. J Biol Chem (2014) 0.80
Tumor necrosis factor-α and interferon-γ stimulate MUC16 (CA125) expression in breast, endometrial and ovarian cancers through NFκB. Oncotarget (2016) 0.77
Aberrant glycosylation of plasma proteins in severe preeclampsia promotes monocyte adhesion. Reprod Sci (2013) 0.75
Pre-eclampsia. Lancet (2005) 10.41
A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. N Engl J Med (1983) 8.82
Mucins in cancer: protection and control of the cell surface. Nat Rev Cancer (2004) 8.06
Reactivity of a monoclonal antibody with human ovarian carcinoma. J Clin Invest (1981) 6.89
Decidual NK cells regulate key developmental processes at the human fetal-maternal interface. Nat Med (2006) 6.54
Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers. Proc Natl Acad Sci U S A (1996) 4.49
Structure and function of the cell surface (tethered) mucins. Annu Rev Physiol (2008) 3.34
Binding of ovarian cancer antigen CA125/MUC16 to mesothelin mediates cell adhesion. J Biol Chem (2003) 3.30
Molecular cloning of the CA125 ovarian cancer antigen: identification as a new mucin, MUC16. J Biol Chem (2001) 2.85
Mesothelin-MUC16 binding is a high affinity, N-glycan dependent interaction that facilitates peritoneal metastasis of ovarian tumors. Mol Cancer (2006) 2.70
The CA 125 gene: an extracellular superstructure dominated by repeat sequences. Tumour Biol (2002) 2.51
Membrane-bound mucins: the mechanistic basis for alterations in the growth and survival of cancer cells. Oncogene (2010) 2.10
Functions of MUC16 in corneal epithelial cells. Invest Ophthalmol Vis Sci (2007) 2.01
MUC16 induced rapid G2/M transition via interactions with JAK2 for increased proliferation and anti-apoptosis in breast cancer cells. Oncogene (2011) 1.86
Human natural killer cell development and biology. Blood Rev (2005) 1.83
Ovarian cancer antigen CA125 is encoded by the MUC16 mucin gene. Int J Cancer (2002) 1.80
Use of CA-125 to assess response to new agents in ovarian cancer trials. J Clin Oncol (2003) 1.78
CA125 antigen levels in obstetric and gynecologic patients. Obstet Gynecol (1984) 1.61
Negative regulation of T cell receptor signaling by Siglec-7 (p70/AIRM) and Siglec-9. J Biol Chem (2004) 1.60
Distribution of CA 125 in embryonic tissues and adult derivatives of the fetal periderm. Am J Obstet Gynecol (1990) 1.53
CA 125 in tissues and amniotic fluid during pregnancy. Am J Obstet Gynecol (1988) 1.45
Siglec-9 enhances IL-10 production in macrophages via tyrosine-based motifs. Biochem Biophys Res Commun (2008) 1.44
The CA 125 gene: a newly discovered extension of the glycosylated N-terminal domain doubles the size of this extracellular superstructure. Tumour Biol (2002) 1.44
Siglec-9, a novel sialic acid binding member of the immunoglobulin superfamily expressed broadly on human blood leukocytes. J Biol Chem (2000) 1.37
Cloning, characterization, and phylogenetic analysis of siglec-9, a new member of the CD33-related group of siglecs. Evidence for co-evolution with sialic acid synthesis pathways. J Biol Chem (2000) 1.35
Potent suppression of natural killer cell response mediated by the ovarian tumor marker CA125. Gynecol Oncol (2005) 1.30
Identification of Siglec-9 as the receptor for MUC16 on human NK cells, B cells, and monocytes. Mol Cancer (2010) 1.30
The cancer antigen CA125 represents a novel counter receptor for galectin-1. J Cell Sci (2003) 1.28
A small region of the natural killer cell receptor, Siglec-7, is responsible for its preferred binding to alpha 2,8-disialyl and branched alpha 2,6-sialyl residues. A comparison with Siglec-9. J Biol Chem (2001) 1.22
Isolation and characterization of ovarian cancer antigen CA 125 using a new monoclonal antibody (VK-8): identification as a mucin-type molecule. Int J Cancer (1997) 1.21
Peritoneal natural killer cells from epithelial ovarian cancer patients show an altered phenotype and bind to the tumour marker MUC16 (CA125). Immunology (2007) 1.16
MUC1 is a counter-receptor for myelin-associated glycoprotein (Siglec-4a) and their interaction contributes to adhesion in pancreatic cancer perineural invasion. Cancer Res (2007) 1.09
Evaluation of 7 serum biomarkers and uterine artery Doppler ultrasound for first-trimester prediction of preeclampsia: a systematic review. Obstet Gynecol Surv (2011) 1.08
First-trimester maternal serum PP13 in the risk assessment for preeclampsia. Am J Obstet Gynecol (2008) 1.08
MUC16 provides immune protection by inhibiting synapse formation between NK and ovarian tumor cells. Mol Cancer (2010) 1.06
MUC16 is lost from the uterodome (pinopode) surface of the receptive human endometrium: in vitro evidence that MUC16 is a barrier to trophoblast adherence. Biol Reprod (2007) 1.05
Immunologic characteristics of preeclampsia, a comprehensive review. Am J Reprod Immunol (2010) 1.04
Multiple hepatic receptors cooperate to eliminate secretory mucins aberrantly entering the bloodstream: are circulating cancer mucins the "tip of the iceberg"? Cancer Res (2006) 1.04
Preeclampsia: current understanding of the molecular basis of vascular dysfunction. Expert Rev Mol Med (2006) 1.03
CA125 (MUC16) tumor antigen selectively modulates the sensitivity of ovarian cancer cells to genotoxic drug-induced apoptosis. Gynecol Oncol (2009) 0.98
CA 125 antigen in human amniotic fluid and fetal membranes. Am J Obstet Gynecol (1986) 0.97
Screening for pre-eclampsia--lessons from aneuploidy screening. Placenta (2011) 0.92
CA125 (MUC16) gene silencing suppresses growth properties of ovarian and breast cancer cells. Eur J Cancer (2011) 0.89
Interaction of human macrophage C-type lectin with O-linked N-acetylgalactosamine residues on mucin glycopeptides. J Biol Chem (1999) 0.89
Characterization of the tumor marker muc16 (ca125) expressed by murine ovarian tumor cell lines and identification of a panel of cross-reactive monoclonal antibodies. J Ovarian Res (2009) 0.87
Biochemical evidence of impaired trophoblastic invasion of decidual stroma in women destined to have preeclampsia. Am J Obstet Gynecol (1996) 0.87
Increased serum CA 125 levels during the first trimester of pregnancy. Acta Obstet Gynecol Scand (1986) 0.86
Maternal serum Ca125 and Ca15-3 antigen levels in normal and pathological pregnancy. Fetal Diagn Ther (2001) 0.85
Tumor markers in hypertensive disorders of pregnancy. Gynecol Obstet Invest (1993) 0.77
Fundamental differences in cell cycle deregulation in human papillomavirus-positive and human papillomavirus-negative head/neck and cervical cancers. Cancer Res (2007) 2.93
Mesothelin-MUC16 binding is a high affinity, N-glycan dependent interaction that facilitates peritoneal metastasis of ovarian tumors. Mol Cancer (2006) 2.70
Characterization of the oligosaccharides associated with the human ovarian tumor marker CA125. J Biol Chem (2003) 1.63
Potent suppression of natural killer cell response mediated by the ovarian tumor marker CA125. Gynecol Oncol (2005) 1.30
Identification of Siglec-9 as the receptor for MUC16 on human NK cells, B cells, and monocytes. Mol Cancer (2010) 1.30
Peritoneal natural killer cells from epithelial ovarian cancer patients show an altered phenotype and bind to the tumour marker MUC16 (CA125). Immunology (2007) 1.16
MUC16 (CA125): tumor biomarker to cancer therapy, a work in progress. Mol Cancer (2014) 1.10
Ascites from epithelial ovarian cancer contain high levels of functional decoy receptor 3 (DcR3) and is associated with platinum resistance. Gynecol Oncol (2008) 1.10
Use of a bupivacaine continuous wound infusion system in gynecologic oncology: a randomized trial. Obstet Gynecol (2005) 1.09
MUC16 provides immune protection by inhibiting synapse formation between NK and ovarian tumor cells. Mol Cancer (2010) 1.06
Expression and roles of Slit/Robo in human ovarian cancer. Histochem Cell Biol (2011) 1.02
Murine and human zona pellucida 3 derived from mouse eggs express identical O-glycans. Proc Natl Acad Sci U S A (2003) 0.96
Ex vivo evaluation of anti-EpCAM immunocytokine huKS-IL2 in ovarian cancer. J Immunother (2004) 0.95
Differential internalization of hu14.18-IL2 immunocytokine by NK and tumor cell: impact on conjugation, cytotoxicity, and targeting. J Leukoc Biol (2011) 0.95
Mesothelin, Stereocilin, and Otoancorin are predicted to have superhelical structures with ARM-type repeats. BMC Struct Biol (2009) 0.93
The detection, treatment, and biology of epithelial ovarian cancer. J Ovarian Res (2010) 0.92
A protocol of dual prophylaxis for venous thromboembolism prevention in gynecologic cancer patients. Obstet Gynecol (2008) 0.91
Terpenoids from Zingiber officinale (Ginger) induce apoptosis in endometrial cancer cells through the activation of p53. PLoS One (2012) 0.90
Endothelial caveolar hub regulation of adenosine triphosphate-induced endothelial nitric oxide synthase subcellular partitioning and domain-specific phosphorylation. Hypertension (2012) 0.89
Differential O-glycosylation of a conserved domain expressed in murine and human ZP3. Biochemistry (2006) 0.88
DcR3 binds to ovarian cancer via heparan sulfate proteoglycans and modulates tumor cells response to platinum with corresponding alteration in the expression of BRCA1. BMC Cancer (2012) 0.88
Ab-IL2 fusion proteins mediate NK cell immune synapse formation by polarizing CD25 to the target cell-effector cell interface. Cancer Immunol Immunother (2011) 0.88
Characterization of the tumor marker muc16 (ca125) expressed by murine ovarian tumor cell lines and identification of a panel of cross-reactive monoclonal antibodies. J Ovarian Res (2009) 0.87
HN125: A Novel Immunoadhesin Targeting MUC16 with Potential for Cancer Therapy. J Cancer (2011) 0.86
The expression of free oligosaccharides in human seminal plasma. J Biol Chem (2002) 0.86
Weekly docetaxel and carboplatin for recurrent ovarian and peritoneal cancer: a phase II trial. Gynecol Oncol (2007) 0.85
Effects of lipopolysaccharide and Mannheimia haemolytica leukotoxin on bovine lung microvascular endothelial cells and alveolar epithelial cells. Clin Vaccine Immunol (2007) 0.85
Biological significance of HORMA domain containing protein 1 (HORMAD1) in epithelial ovarian carcinoma. Cancer Lett (2012) 0.85
Analysis of protein-linked glycosylation in a sperm-somatic cell adhesion system. Glycobiology (2007) 0.82
Sonohysterography and endometrial cancer: incidence and functional viability of disseminated malignant cells. Am J Obstet Gynecol (2008) 0.82
Laparoscopic sentinel lymph node mapping for cervix cancer--a detailed evaluation and time analysis. Gynecol Oncol (2007) 0.81
Quality of life in cervical cancer survivors: patient and provider perspectives on common complications of cervical cancer and treatment. Gynecol Oncol (2011) 0.81
Effects of extracellular ATP on bovine lung endothelial and epithelial cell monolayer morphologies, apoptoses, and permeabilities. Clin Vaccine Immunol (2008) 0.81
Formulation, Characterization, and Antitumor Properties of Trans- and Cis-Citral in the 4T1 Breast Cancer Xenograft Mouse Model. Pharm Res (2015) 0.80
Intraoperative autologous blood transfusion use during radical hysterectomy for cervical cancer: long-term follow-up of a prospective trial. Arch Gynecol Obstet (2012) 0.80
A phase 1b study of humanized KS-interleukin-2 (huKS-IL2) immunocytokine with cyclophosphamide in patients with EpCAM-positive advanced solid tumors. BMC Cancer (2013) 0.78
Pregnancy ameliorates the inhibitory effects of 2-methoxyestradiol on angiogenesis in primary sheep uterine endothelial cells. Reprod Sci (2011) 0.76
Estradiol 17β and its metabolites stimulate cell proliferation and antagonize ascorbic acid-suppressed cell proliferation in human ovarian cancer cells. Reprod Sci (2013) 0.76
Uterine leiomyosarcoma diffusely express disialoganglioside GD2 and bind the therapeutic immunocytokine 14.18-IL2: implications for immunotherapy. Cancer Immunol Immunother (2012) 0.76
RT-SVR+q: a strategy for post-Mascot analysis using retention time and q value metric to improve peptide and protein identifications. J Proteomics (2011) 0.75
The immunomodulating roles of glycoproteins in epithelial ovarian cancer. Front Biosci (Elite Ed) (2012) 0.75
Effect of acetyl-l-carnitine on ovarian cancer cells' proliferation, nerve growth factor receptor (Trk-A and p75) expression, and the cytotoxic potential of paclitaxel and carboplatin. Gynecol Oncol (2009) 0.75
Plasmonic Nanoparticle-based Digital Cytometry to Quantify MUC16 Binding on the Surface of Leukocytes in Ovarian Cancer. ACS Sens (2020) 0.75
Use of natural teeth in an interim partial denture. Gen Dent (2002) 0.75